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ABSTRACT
Objectives: As part of the National Institute for
Health and Clinical Excellence (NICE) Single
Technology Appraisal (STA) process, manufacturers
present submissions outlining the clinical and cost-
effectiveness of new technologies. These
submissions are critically appraised by Evidence
Review Groups (ERGs), who produce a report, which
forms part of the evidence considered by the NICE
Appraisal Committees. The purpose of this research
was first to identify common issues and concerns
identified by the ERGs in their analyses of
manufacturers’ submissions (MS). The aim was then
to use these as a basis to develop feedback for
manufacturers.
Design: A qualitative study using a content analysis
approach to examine two sources of evidence, the first
30 ERG reports and 21 clarification letters associated
with these STAs.
Setting: UK HTA programme.
Primary and secondary outcome
measures: Common issues and concerns in MS.
Results: There were positive comments regarding the
quality of the MS, many of which were clearly written.
The majority, however, were generally of poor quality
and issues and concerns identified across the ERG
reports and clarification letters included: criticisms
related to the data being used especially data
employed in the cost-effectiveness model, failure to
perform a necessary analysis and poor reporting of
processes used in the MS. Aspects of the decision
problem were also often poorly or inadequately
addressed by manufacturers. The majority of points
raised for clarification related to the economic data
analysis. Internal inconsistencies between the clinical
and economic sections of the submission were
frequently highlighted. These were used as the basis
for the development of 12 suggestions for
manufacturers.
Conclusions: Much can be done to improve the
quality of MS in the NICE STA process. Suggestions
include the need for clear and transparent reporting of
methods and analyses.
INTRODUCTION
The National Institute for Health and Clinical
Excellence (NICE) produces technology
appraisals using clearly defined processes,
which lead to recommendations on the use of
new and existing medicines and treatments
within the NHS.1 This guidance is currently
mandatory in the NHS in England and Wales,
giving NICE the potential to decrease varia-
tion in the provision of healthcare. The
Single Technology Appraisal (STA) process
was introduced in 2005 and was specifically
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ARTICLE SUMMARY
Article focus
- As part of the NICE STA process, ERGs critically
appraise manufacturer submissions in their
reports and write clarification letters requesting
more information from manufacturers. Two
sources of evidence, ERG reports and the
clarification letters associated with these STAs
were analysed using a content analysis approach.
The aim of this study was to identify issues and
concerns identified by the ERGs in their analyses
of submissions and use these to develop
feedback to manufacturers.
Key messages
- A qualitative analysis of 30 ERG reports and 21
clarification letters was undertaken to identify
recurring issues and concerns in manufacturers’
submissions. The issues and concerns identified
in this analysis were used to inform the
development of a set of 12 suggestions to
manufacturers to improve the quality of future
submissions to NICE.
Strengths and limitations of this study
- The research study applied validated methods
and used multiple reviewers to check and verify
data and analyses. Only the first 30 completed
ERG reports and 21 associated clarification
letters were examined in this analysis. There
may be some misinterpretations in these anal-
yses as documentary analysis was the only
method used.
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designed to appraise a new technology for a single indi-
cation and produce guidance as close to market author-
isation as possible. The pressures that initiated this
imperative are many and come from government,
patients, patient organisations, clinicians and as would be
expected the pharmaceutical manufacturers.
In the STA process, the manufacturers’ submission
(MS) to NICE provides the clinical and cost-effectiveness
data from which the appraisal proceeds. NICE has
provided a standard report template and extensive
guidance for manufacturers to assist them in the prep-
aration of their submissions.2 The MS is expected to
include a systematic review of the clinical and cost-
effectiveness evidence for the technology under consid-
eration as well as a cost-effectiveness analysis, which, as
standard, includes the submission of an economic model
demonstrating their view of the cost-effectiveness of the
technology. The introduction of the STA process initially
raised concerns that basing decisions on submissions
from the manufacturers had the potential to provide
a less robust process for producing guidance than the
original NICE multiple technology appraisal (MTA)
process. For MTAs, the evidence is identified and
appraised by independent academic groups.3 Issues
continue to be raised regarding the rigour and timeli-
ness of the STA process.4 5 A recent analysis of the
timings and outcomes of the STA process showed that it
is not as rapid as originally anticipated.6
For STAs, external independent Evidence Review
Groups (ERGs) are charged with the task of critically
appraising the MS by identifying strengths, weaknesses
and gaps in the evidence presented. The resultant ERG
reports then form a part of the evidence considered by
the NICE Appraisal Committees (ACs). As part of the
process, the ERG has the opportunity to request more
information from the manufacturer in the form of
a clarification letter sent 2 weeks after the submission has
been received. ERGs are expected to appraise critically
the MS to determine whether the clinical and economic
evidence presented is:
< relevant to the issue under consideration in terms of
patient groups, comparators, perspective and
outcomes;
< complete (all relevant evidence identified);
< inclusive of all study design information (including
the type of study, the circumstances of its undertaking
and the selection of outcomes and costs) and
inclusive of all intention-to-treat patients;
< fit for purpose (contributing to an overall assessment
of the clinical benefit and quality of life, preferably in
such units that allow comparison of the benefits from
different technologies and between different patient
groups);
< methodologically sound in that the presented anal-
yses and modelling are replicable, have face validity
and are open to external scrutiny.
Common issues associated with the MS for the NICE
MTA process were explored by Burls and Sandercock7 in
their tongue-in-cheek paper in the BMJ’s Christmas issue
in 2003 (eg, choice of comparators, length of follow-up
and study selection). Miners et al8 also highlighted the
significantly lower estimated cost-effectiveness ratios
submitted by manufacturers compared to those
submitted by the independent assessment groups in the
NICE MTA process. Although the STA process is
different, and extensive scoping is carried out to provide
a comprehensive decision problem, which guides the
STA process, many of the same approaches continue to
be used by manufacturers in their STA submissions to
NICE.
There is currently uncertainty regarding the future of
the NICE technology appraisal process.9 However, these
issues will still be relevant in any process where submis-
sions from manufacturers are provided as part of the
evidence used to make decisions regarding new treat-
ments. The purpose of this research study was to identify
common issues and concerns identified by the ERGs in
their analyses of MS and to use these as a basis to provide
feedback to manufacturers to assist them in future
submission development as well as recommendations to
the ERGs and NICE. The suggestions for manufacturers
are presented in this paper.
METHODS
Two sources of information were used to identify
common issues and concerns with MS: the first 30
completed ERG reports and 21 associated clarification
letters. These are presented in detail in Kaltenthaler
et al10 and summarised briefly here. The 30 ERG reports
and their related letters were anonymised, and none is
referred to explicitly in this paper.
Twenty-one clarification letters were available, relating
to the first 30 STAs. The use of clarification letters was
not part of the original STA process so a number of the
early reports did not have letters. The clarification letters
were examined, and data were extracted using a set of
open codes with definitions to categorise data. Initial
data coding was conducted by one reviewer (RD) and
included clinical and economic issues, indirect compar-
isons, licensing, systematic review methods and report
quality. After initial coding, the reviewer (RD) examined
and categorised the clinical and report quality points
into three groups: reporting of systematic review
methods, clinical data and report quality. Two reviewers
(PF and AB) regrouped and categorised the economic
data into three categories: clarification/explanation,
data/methods and further analyses.
A documentary analysis of the first 30 ERG reports was
undertaken. For this research, we were exclusively
interested in the content, rather than the context of the
reports. Extraction of relevant data from the ERG
reports was conducted by three team members (AB, CC
and PF) using forms developed for this project and
piloted on two ERG reports by all three reviewers. The
aim of the extraction was to retrieve data on key
elements of the processes undertaken by ERGs and the
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strengths and weaknesses of the MS. Much of these data
consisted of text, that is, statements or summaries by the
ERG. Thematic analysis11 was the method chosen to
analyse these data as it is grounded in the data and
therefore permits the generation of a novel thematic
framework reflecting the ERGs’ assessments of the
strengths and weaknesses of MS to the STA process. This
interpretive process was initially performed by one
reviewer (CC) on the extractions from a random sample
of 10 ERG reports. If themes identified in this way were
considered to be related, then they were placed under
a broader theme that captured them all. Definitions
were then developed for each theme in order to produce
greater reliability in the coding of data. Two members of
the project team (RD and EK) then independently
assessed whether these thematic interpretations of the
data were both credible and appropriate and whether
the themes identified reflected the data therein. This led
to a small number of revisions and some further clarifi-
cation of the themes’ definitions. The extracted textual
data from the remaining 20 ERG reports were then
coded using these agreed themes following a process
akin to that outlined in framework analysis.12 This was
performed by two reviewers (CC and EK) each working
on the data extracted from half of the remaining 20 ERG
reports.
From these two sources, common issues and concerns
were identified and these formed the basis for the
development of feedback for manufacturers to improve
the quality and content of their MS.
RESULTS
Clarification letter analysis
Over 400 points from the clarification letters were
analysed and presented in four main categories: ‘report
quality’, ‘systematic review methods’, ‘clinical data’ and
‘economic data analysis’.
The ‘report quality’ category covered general issues
related to the overall quality of the MS as well as errors
and inconsistencies. Also included in this category were
issues related to the presentation of data and absence of
information. In the ‘systematic review methods’ category,
there were issues related to searching and study selec-
tion, decisions regarding inclusion criteria and general
methods issues. The comments indicated that manufac-
turers often failed to report the use of robust methods
for the conduct of their systematic reviews. The ‘clinical
data’ category included points related to specific clinical
questions, requests for additional clinical data, explana-
tions or further analyses and provision of rationale for
the analyses that had been undertaken. Requests
included a number of issues such as additional subgroup
analysis, use of end points and outcomes and, most
frequently, queries around the use of indirect and mixed
treatment comparisons.
The majority of clarification points related to the
‘economic data analysis’ category and covered issues
such as clarification of data sources and choices, queries
about modelling decisions and requests for additional
analyses. Internal inconsistencies between the clinical
and economic sections of the submission and inconsis-
tencies within the economic section of the MS were
identified as particular problems highlighted in the
clarification letters.
ERG report analysis
There were many positive comments in the ERG reports
regarding the quality and reporting of the MS. However,
for the purpose of this analysis, it is the main short-
comings and/or inconsistencies that are presented. The
thematic analysis generated a large number of themes
and from these five broader themes emerged. These five
themes related to ‘processes’, ‘reporting’, ‘satisfaction of
objectives’, ‘reliability and validity’ and ‘content’.
The ‘processes’ theme related to interpretations of
ERG comments on the conduct or performance of the
systematic review and cost-effectiveness modelling within
the MS, in particular the conduct of analyses. More than
half (17/30) of the ERG reports explicitly criticised the
conduct of the systematic review within the MS, for
example, the quality of the searching, screening or
quality assessment processes, the definition or applica-
tion of inclusion criteria, the presence of errors or
failure to perform meta-analyses or even the complete
absence of a formal systematic review. Criticisms related
to the manufacturers’ analyses covered both failure to
perform a necessary analysis (12/30 reports) and the
performance of an inappropriate analysis (17/30
reports). Two-thirds (20/30) of ERG reports contained
criticisms related to the data being used, especially data
employed in the cost-effectiveness model.
The ‘reporting’ theme referred to ERG comments on
the quality of the manufacturers’ description of the
conduct of both the reviewing and modelling. The vast
majority (27/30) of ERG reports identified inadequate
reporting of processes in the MS. These included limited
descriptions of searching, prohibiting replication and
lack of transparency in the description of the processes
used in the clinical review process generally for both
direct and indirect comparisons. The manufacturers’
limited reporting of the cost-effectiveness model was the
most common criticism (11/30 reports) and included
failure to describe adequately either the parameters or
assumptions behind the model, the generation or source
of various values or the impact of bias from missing data.
The four categories identified in the clarification
letters translate into these two themes of ‘processes’
and ‘reporting’ derived from the overall ERG analysis.
This is because the letters concern the choice and/or
provision of data (processes) and clarifications on
what the manufacturer had actually done (reporting).
The following three themes reflect more the overall
submission.
The ‘satisfaction of objectives’ theme referred to issues
related to the decision problem (population, interven-
tion, comparator, outcomes and NICE base case) and
whether or not these were satisfactorily addressed in the
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MS. Twenty of the 30 ERG reports raised issues with the
trial populations presented in the MS and 18/30 raised
various issues with the comparators. By contrast, few
ERGs reported that the MS did not satisfy the interven-
tion or outcome elements of the decision problem. The
majority of submissions appear to have adhered to the
NICE base-case scenario and prompted no criticism.
The ‘reliability and validity’ theme was related to issues
on the robustness or limitations of the MS findings. A
total of 27/30 ERG reports stressed the presence of
uncertainty within the analyses, thus highlighting the
lack of certainty surrounding the results presented in the
MS. The principal causes of uncertainty identified by the
ERGs concerned the exaggerated effect of the tech-
nology from the analysis, especially the relative efficacy
of the technology versus relevant comparators; the safety
of the technology and uncertain levels of risk for
different populations.
The ‘content’ theme referred to the amount and
quality of trial evidence presented in the MS. This
attracted comments from the ERGs when only one or
two randomised controlled trials were evaluated in the
MS; where there were few head-to-head trials available
for inclusion and/or the quality of the included trials
was poor.
Suggestions for manufacturers
From the thematic analysis of the ERG reports and
clarification letter analysis, it was possible for the team to
identify key suggestions for ways to improve the quality
of evidence submitted to NICE by manufacturers. These
were developed further at a workshop held in April 2010
with 50 participants from 10 ERG groups, the National
Institute for Health Research (NIHR) Evaluation, Trials
and Studies Coordinating Centre (NETSCC) and NICE.
These suggestions are shown in box 1.
DISCUSSION
This research used ERG reports and clarification letters
as sources of information to identify common issues and
concerns with evidence submissions from manufacturers
as part of the NICE STA process. It is worth emphasising
that the ERGs made many positive comments about the
submissions included in this study. The analysis of the
ERG reports did, however, identify criticisms of the
conduct of the systematic review within the MS as well as
criticisms of the data being used, especially data
employed in cost-effectiveness models. Major issues
regarding poor reporting of processes used in the MS
were also identified. The majority of clarification points
related to economic data analysis and covered issues
such as inconsistencies between the clinical and
economic sections of the submission, queries regarding
sources of data and their use in the economic analysis,
questions about modelling decisions, data queries and
requests for additional analysis. These issues covered
both what evidence was presented by manufacturers and
how it was presented. They highlight the frequent lack of
clarity regarding methods of review synthesis and
methods used for indirect comparisons. The inconsis-
tencies within the MS reflect that several groups within
the pharmaceutical company may contribute to each
MS.
The analysis of the ERG reports applied validated
methods and used multiple reviewers to check and verify
data and analyses. All data used in this analysis were
available on the NICE website (http://www.nice.org.uk)
and therefore in the public domain. Only the first 30
completed ERG reports were included due to time and
resource constraints. These were the first 30 STAs and
some of the critical appraisal methods currently used by
the ERG teams have been developed over time and may
not be accounted for in these analyses. At the time of
writing (December 2011), the ERG reports for 94 STAs
had been completed so the analysis presented here
includes approximately a third of completed STAs to
date. There may be some misinterpretations in these
analyses as documentary analysis was the only method
used. Analysis was limited to what was reported in the
ERG reports. The research would have been strength-
ened by interviewing manufacturers, ERGs and NICE to
gain a more in-depth understanding of the issues. This
research dealt with the ERGs’ interpretations of
Box 1 Suggestions for manufacturers for the preparation
of submissions to the NICE STA process
1. Manufacturer submissions should be comprehensive,
clearly written, appropriately copy edited and internally
consistent.
2. Definitions for all key terms and abbreviations in the
manufacturers’ submissions (MS) should be provided.
3. There should be transparency in the reporting of
methods and analyses.
4. Where applicable, reviews should adhere to internation-
ally accepted standards for conducting and reporting
reviews.
5. Where there is a single clinical study, the study report
and protocol should be an addendum to the submission.
6. There should be clear reporting of methods and results
used for indirect comparisons.
7. The submission should provide relevant and sufficiently
detailed data related to clinical progression, outcomes
and adverse events.
8. There should be clear and concise rationale for the
synthesis of clinical data.
9. Clear rationale should be provided for the types of
analyses chosen for use in the submission.
10. There should be clear and concise rationale for the
development of economic models and the assumptions
used to develop models need to be provided.
11. A systematic identification and selection of utility values
should be included where appropriate in the MS.
12. Reviewing of model parameter values should be
comprehensive and transparent. How comprehensive
depends on how critical the parameter is to the
appraisal.
4 Kaltenthaler EC, Dickson R, Boland A, et al. BMJ Open 2012;2:e000562. doi:10.1136/bmjopen-2011-000562
A qualitative study of manufacturer’s submissions to the NICE STA process
manufacturers’ submissions. It was beyond the remit of
this work to explore the actual submissions themselves or
the relationship between the quality of submissions and
subsequent decisions as well as changes in submissions
over time. These are potential areas of further research.
Only 21 clarification letters were examined in this anal-
ysis as some early STAs did not have clarification letters
and others were unavailable. The approach provides an
important overview of the commonalities of the queries
put forward in the clarification letters. Clarification
letters are currently being developed using a more
structured approach. Recently, NICE has made changes
to the MS template through a consultation process. All
these changes may impact on the issues presented here,
although the team involved in this research continues to
be involved in the NICE STA process and feels that the
issues will remain the same in the near future.
Many of the issues identified in this analysis are similar
to those identified by Hill et al13 in their review of the
economic analyses submitted as part of the appraisal
process in Australia. Of the 249 problems identified in
their analysis, 154 (62%) related to uncertainty in the
estimates of comparative clinical efficacy and 71 (28.5%)
related to modelling issues, which included clinical
assumptions or cost estimates, used in the construction
of the economic models.
There has been much speculation regarding the
future of NICE and the STA process.14e16 Although the
future of the NICE STA process is unclear, these
suggestions are relevant to any subsequent process,
which involves the production of a submission of
evidence by manufacturers. NICE is set to retain its role
in recommending drugs for use in the NHS within the
new value-based pricing approach,17 and the same sorts
of information will be needed to inform the decision-
making process. Claxton et al18 discussed some of the
pros and cons of value-based pricing several years ago
and argued that the cost-effectiveness threshold has
a key role and that its assessment should be transparent
and based on independent scientific analysis. As NICE
moves towards the use of value-based pricing in January
2014, in spite of misgivings reported during the consul-
tation process,19 issues about the definition of ‘value’ in
medical terms will be central and have implications for
other countries.20 For many drugs going through the
STA process, available clinical data (relevant population
and/or comparator) do not meet the decision problem
or do not represent the UK population, and standard
treatment will vary between countries. This makes it
crucial that any decision-making process that relies on
the submission of evidence by manufacturers will require
a clearly written and internally consistent submission
with justification for the use of data sources.
The relationship between the quality of the MS and
the effect this has on the ability of the AC to make an
informed decision on a technology has not yet been
clearly investigated and this warrants further research.
This work should include evaluation and monitoring of
submissions to determine whether or not the suggestions
set out here have been heeded by manufacturers. Manu-
facturers should be offered training and support to
ensure that submissions meet the needs of the AC.
Further research should explore with manufacturers how
they have changed their submissions based on past
experience with the STA process and the types of issues
that have been raised in clarification letters. Improved
dialogue with manufacturers will ensure the development
of a better understanding of the need for clear submis-
sions. It is hoped that uptake of these suggestions by
manufacturers will result in more transparent and inter-
nally consistent submissions and will improve the effi-
ciency of the current NICE STA process and any
subsequent process. The poor quality of submissions can
cause delays to the process as there may be the need for
further data requests from manufacturers before the AC
can make a decision. The poor quality of submissions does
also mean that the key issues may not be explored fully by
the ERGs and therefore by the AC, potentially having an
impact on the decisions that are made. The appraisal and
decision-making process would be enhanced and facili-
tated by the improvements suggested here.
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